Delaware
|
001-37566
|
26-1824804
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
301 Binney St., Suite 402
Cambridge, MA
|
02142
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
SYBX
|
The Nasdaq Capital Market
|
SYNLOGIC, INC. |
|||
Date: May 9, 2019 |
By: |
/s/ Todd Shegog | |
Name: |
Todd Shegog |
||
Title: |
Chief Financial Officer |
Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
– Company will host a conference call and webcast at 5:00 pm ET today –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2019--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the first quarter ended March 31, 2019.
“We made significant progress on our 2019 goals in the first quarter of the year providing a strong foundation for the continued development of our Synthetic Biotic™ platform and clinical pipeline,” said Aoife Brennan, M.B., Ch.B. Synlogic’s president and chief executive officer. “We strengthened our scientific leadership with the appointment of two experienced drug developers, Dr. Scott Plevy, as Chief Scientific Officer, and Dr. Patricia Hurter, who joined our board of directors and brings additional relevant experience in manufacturing. In addition, we have manufactured clinical trial material in-house for our IO program and made significant advances in developing processes to reliably and reproducibly manufacture solid formulations of our orally administered Synthetic Biotic medicines. The new formulation has a more patient-friendly stability profile and provides a path to longer out-patient studies and eventual commercialization.”
Recent Highlights
Corporate
Pipeline
First Quarter 2019 Financial Results
For the three months ended March 31, 2019, Synlogic reported a consolidated net loss of $12.9 million, or $0.51 per share, compared to a consolidated net loss of $11.2 million, or $0.55 per share, for the corresponding period in 2018. The increase in net loss was primarily due to increases in compensation-related expenses due to increased headcount, as well as increases in research and development expenses to support Synlogic’s advancing clinical programs.
Research and development expenses were $10.4 million for the three months ended March 31, 2019 compared to $8.4 million for the corresponding period in 2018. The increase was primarily due to an increase in compensation-related expenses associated with increased headcount and increased expenses associated with manufacturing and pre-clinical and clinical studies of Synlogic’s Synthetic Biotic programs.
General and administrative expenses for the three months ended March 31, 2019 were $3.7 million compared to $3.6 million for the corresponding period in 2018.
Revenue was $0.3 million for the three months ended March 31, 2019 compared to $0.4 million for the same period in 2018. Revenue for both periods is associated with services performed under Synlogic’s collaboration with AbbVie to develop a Synthetic Biotic medicine for the treatment of IBD.
As of March 31, 2019, Synlogic had cash, cash equivalents, and short-term investments of $109.8 million.
Conference Call & Webcast Information
Synlogic will host a conference call and live webcast today at 5:00 pm ET today, Thursday, May 9, 2019. To access the live webcast, please visit the “Event Calendar” page within the Investors and Media section of the Synlogic website. Alternatively, investors may listen to the call by dialing +1 (844) 815-2882 from locations in the United States or +1 (213) 660-0926 from outside the United States. The conference ID number is 2154739. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Investors and Media section of the Synlogic website.
About Synlogic
Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company’s two lead programs, SYNB1020 and SYNB1618, target hyperammonemia as a result of liver damage or genetic disease, and PKU, respectively. When delivered orally, Synthetic Biotic medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic’s platform to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, liver disease, inflammatory and immune disorders, and cancer; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic’s technology to treat hyperammonemia and phenylketonuria; and the expected timing of Synlogic’s anticipated clinical trial initiations. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Synlogic’s filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic’s view as of any date subsequent to the date hereof.
|
|
|
||||||||||
Synlogic, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||
(unaudited) | ||||||||||||
(in thousands except share and per share data) | |
|
|
For the three months ended | ||||||||
|
|
|
|
|
March 31, 2019 | |
|
March 31, 2018 | ||||
|
|
|
|
|
|
|
|
|||||
Revenue | |
|
|
$ | 338 | |
|
|
$ | 354 | |
|
|
|
|
|
|
|
|
|
|||||
Operating expenses | |
|
|
|
|
|
|
|||||
Research and development | |
|
|
|
10,384 | |
|
|
|
8,361 | |
|
General and administrative | |
|
|
3,651 | |
|
3,629 | |||||
Total operating expenses | |
|
|
14,035 | |
|
11,990 | |||||
Loss from operations | |
|
|
|
(13,697 | ) | |
|
|
(11,636 | ) | |
Other income(expense), net | |
|
|
751 | |
|
471 | |||||
Net loss | |
|
|
$ | (12,946 | ) | |
|
$ | (11,165 | ) | |
|
|
|
|
|
|
|
|
|||||
Net loss per share attributable to common |
|
|
|
$ | (0.51 | ) | |
|
$ | (0.55 | ) | |
Weighted-average common shares used in |
|
|
|
25,293,791 | |
|
20,145,881 | |||||
|
|
|
|
|
|
|
|
|
|
|
||||||||
Synlogic, Inc. | ||||||||||
Condensed Consolidated Balance Sheets | ||||||||||
(unaudited) | ||||||||||
(in thousands) | |
|
|
|
|
|
|
|||
|
|
|
|
|
March 31, 2019 | |
|
December 31, 2018 | ||
Assets | |
|
|
|
|
|
|
|||
Cash, cash equivalents and short-term investments | |
|
|
$ | 109,835 | |
|
$ | 122,729 | |
Fixed assets | |
|
|
|
14,348 | |
|
|
14,841 | |
Other assets | |
|
|
19,836 | |
|
2,770 | |||
Total assets | |
|
|
$ | 144,019 | |
|
$ | 140,340 | |
|
|
|
|
|
|
|
|
|||
Liabilities and Stockholders' Equity | |
|
|
|
|
|
|
|||
Current liabilities | |
|
|
$ | 9,721 | |
|
$ | 8,341 | |
Long-term liabilities | |
|
|
22,089 | |
|
7,901 | |||
Total liabilities | |
|
|
31,810 | |
|
16,242 | |||
Total stockholders' equity | |
|
|
112,209 | |
|
124,098 | |||
Total liabilities and stockholders' equity | |
|
|
$ | 144,019 | |
|
$ | 140,340 | |
|
|
|
|
|
|
|
|
CONTACT:
MEDIA:
Synlogic
Courtney Heath
Phone: 617-872-2462
Email: courtney@scientpr.com
INVESTORS:
Synlogic
Elizabeth Wolffe, Ph.D.
Phone: 617-207-5509
Email: liz@synlogictx.com